Biopharmaceuticals

Cambridge, Mass. – September 15, 2026 -- Vincere Biosciences has been awarded a $2.7 million Small Business Innovation Research (SBIR) Phase II grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health, to fund IND-enabling development of its USP30 inhibitor for acute kidney injury (AKI).

NIH funding targets a disease affecting 13 million people annually

Acute kidney injury impacts more than 13 million people worldwide each year following ischemia, major surgery, or exposure to nephrotoxic drugs, yet treatment remains largely supportive. The two-year grant will fund genotoxicity and toxicology studies, 28-day GLP toxicology studies, and cardiovascular, respiratory, and CNS safety pharmacology required before Vincere can file an Investigational New Drug (IND) application.

Tel Aviv and Oslo – September 15, 2026 -- BioLineRx Ltd. (NASDAQ/TASE: BLRX) and Hemispherian AS will present two abstracts on their oncology candidate GLIX1 at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) in Rome, Italy, September 24-27, with one abstract selected for oral presentation.

Burlington, N.C. – September 15, 2026 -- Labcorp (NYSE: LH) reaffirmed its full-year 2026 guidance and unveiled a long-term outlook through 2029 projecting compound annual revenue growth of 5% to 8% and compound annual adjusted earnings per share growth of 8.5% to 11.5%, the company said at its 2026 Investor Day.

Labcorp projects adjusted operating margin expansion of 75 to 150 basis points by 2029

The diagnostics and drug development laboratory company also targets compound annual free cash flow growth in line with adjusted earnings growth through the same period. Guidance assumes foreign exchange rates effective as of June 30, 2026, and reflects anticipated capital allocation including acquisitions, share repurchases and dividends.

Delft – September 15, 2026 -- AdJane Biosciences has published a White Paper outlining a strategy to add a proprietary intranasal booster to existing intramuscular respiratory vaccines, targeting the mucosal immunity gap left by current mRNA shots.

Phase I data show intranasal booster induced significant nasal IgA responses in mRNA-primed subjects

In a post-hoc subset of participants from AdJane's completed Phase I study who had previously received Pfizer and/or Moderna COVID-19 mRNA vaccines, a subsequent intranasal dose of an Nm-nOMV vaccine displaying SARS-CoV-2 Spike was well tolerated and generated significant nasal IgA responses. AdJane says this provides initial human evidence for a heterologous prime-boost approach: systemic priming via existing intramuscular vaccines followed by a mucosal Nm-nOMV booster delivered intranasally.

Delft – September 15, 2026 -- AdJane Biosciences has published a white paper outlining a strategy to add mucosal immune stimulation to existing intramuscular respiratory vaccine regimens, using its clinically validated Nm-nOMV platform derived from Neisseria meningitidis outer membrane vesicles.

AdJane targets the mucosal gap left by intramuscular respiratory vaccines

Current intramuscular respiratory vaccines induce strong systemic immunity and protect against severe disease, but generate limited protection at the respiratory mucosa, the point where pathogens first enter the body. The company's white paper, titled 'Boosting mRNA: Mucosal Immunity and a Platform Beyond It,' argues that mucosal IgA responses can reduce transmission at the point of entry, a target public health bodies are pursuing alongside severe-disease prevention.

Basel, Switzerland – September 15, 2026 -- CordenPharma has committed a multi-year €80 million investment to expand sterile injectable manufacturing at its FDA & EMA-approved Caponago site near Milan, Italy, targeting a total production capacity of 500 million units per year.

CordenPharma finalizes €13 million land and building acquisition to expand Caponago footprint by over 50%

The company completed the purchase of an 11,000 m2 commercial building and 26,000 m2 of adjacent land on 28 July 2026, adjacent to its existing late-stage aseptic fill & finish area. The new space can accommodate at least four aseptic fill & finish lines, four visual inspection lines and four packaging lines, with room for customer-owned lines, large-scale lyophilization and auto-injector assembly.

Basel – September 15, 2026 -- CordenPharma has committed a multi-year €80 million investment to expand sterile injectable manufacturing at its Caponago, Italy site, targeting total production capacity of up to 500 million injectable units per year.

Cambridge – – September 15, 2026 -- Insilico Medicine (HKEX: 3696) has dosed the first patient in GENESIS-IPF-3, a Phase III trial of Rentosertib, marking what the company calls the world's first late-stage clinical study of a drug candidate discovered and developed using generative AI.

Peking and Shanghai hospitals simultaneously enroll first patients

The dosing occurred at Peking Union Medical College Hospital, with Shanghai Pulmonary Hospital enrolling its own first patient on the same day. Professor Zuojun Xu of Peking Union Medical College Hospital serves as Leading Principal Investigator, with Academician Nanshan Zhong and President Chang Chen of Shanghai Pulmonary Hospital as Co-Leading PIs.

Durham – September 15, 2026 -- Seismic Pharmaceuticals has enrolled the first patient in RESCUE HF-CS, a global Phase 3 trial testing istaroxime as a potential first-ever approved drug for heart-failure-related cardiogenic shock, a condition with no FDA-approved treatment.

Trial to enroll 600 patients across four continents

The study will recruit approximately 600 patients at clinical sites in the United States, Europe, China and South America. It builds on four completed Phase 2 trials that enrolled more than 350 patients.

Cardiogenic shock carries high mortality despite critical care advances

The condition occurs when the heart cannot pump enough blood to meet the body's needs, cutting oxygen delivery to vital organs. It often complicates acute heart failure or other serious cardiac events, and no pharmacologic therapy has been developed specifically to treat it.

Durham – September 15, 2026 -- Seismic Pharmaceuticals has commenced a global Phase 3 trial of Istaroxime, aiming to deliver the first-ever approved drug for cardiogenic shock, a condition with no currently FDA-approved treatments.

Trial to enroll 600 patients across three continents

The study, named Rescue HF CS, will recruit approximately 600 patients at clinical sites in the United States, Europe and South America. It builds on four completed Phase 2 trials in which more than 340 patients received Istaroxime.